Immedica expands its management team - Nina Fleck and Håkan Garpenstrand joins Immedica

Nina Fleck and Håkan Garpenstrand joins Immedica, the pan-European specialty pharma commercialization and distribution pharma company. Nina Fleck and Håkan Garpenstrand will be instrumental in supporting Immedica’s plan to quickly establish itself as a leading pan-European niche specialty pharma company with a portfolio composed of partner products as well as proprietary product rights.

Immedica is proud to have recruited Nina Fleck as Vice President and General Counsel and Håkan Garpenstrand as Vice President and Head of Business Development.

Nina Fleck, most recently serving as Vice President Corporate Development at Sobi and prior to that as Senior Legal Counsel at Sobi, has a vast experience from contracting various types of partnership agreements in the specialty care area, as well as all aspects of corporate law in the pharmaceutical field.

Håkan Garpenstrand, most recently Vice President and Head of Corporate Development at Sobi, has a very successful track record of pharmaceutical deal making at Sobi as well as in previous big pharma positions. He has a very broad pharma industry background and has for more than 20 years held both R&D and commercial management positions in international companies.

Immedica has today a portfolio of 15 drugs and a strong organic annual growth trajectory, and as a consequence of its significant scale up of activities the company is planning to add several key positions across Europe.

About Immedica

Immedica is a fast-growing private European niche pharma company. The company is based in Stockholm, Sweden, and has a pan-European commercial coverage with the Nordic as its stronghold.

Immedica provides significant know-how and experience from commercialization of niche/specialty care products across the European and Middle East territories, and the company’s management team has an outstanding track record of operating niche pharma products in Europe. Immedica has capabilities to provide optimal access of specialty care medicines to patients with significant medical needs, including key areas such as regulatory affairs, pharmacovigilance, medical affairs, pricing & reimbursement, and product distribution.

Today, Immedica manage many of its products via operations at Medical Need Europe, a niche/orphan pharma company recently acquired. Immedica’s main owner is Impilo AB, a private Swedish Health Care investment company established in 2017, and with more than SEK 3.5 billion in capital from leading Nordic and international investors. More information is available at www.immedica.com  or www.medicalneed.com

For more information

Anders Edvell, CEO, Immedica

anders.edvell@immedica.com

+46 705 44 61 26